239 related articles for article (PubMed ID: 35897763)
1. Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models.
Rupp T; Debasly S; Genest L; Froget G; Castagné V
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897763
[TBL] [Abstract][Full Text] [Related]
2. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models.
Rupp T; Pelouin O; Genest L; Legrand C; Froget G; Castagné V
Transl Oncol; 2021 Jan; 14(1):100926. PubMed ID: 33157518
[TBL] [Abstract][Full Text] [Related]
4. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
11. Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.
Diem L; Daponte A; Findling O; Miclea A; Briner M; Salmen A; Gold R; Kilidireas C; Chan A; Evangelopoulos ME; Hoepner R
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31937596
[TBL] [Abstract][Full Text] [Related]
12. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
[TBL] [Abstract][Full Text] [Related]
13. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
Prosperini L; Lucchini M; Haggiag S; Bellantonio P; Bianco A; Buscarinu MC; Buttari F; Centonze D; Cortese A; De Giglio L; Fantozzi R; Ferraro E; Fornasiero A; Francia A; Galgani S; Gasperini C; Marfia GA; Millefiorini E; Nociti V; Pontecorvo S; Pozzilli C; Ruggieri S; Salvetti M; Sgarlata E; Mirabella M
Neurology; 2018 Jul; 91(2):e153-e161. PubMed ID: 29875218
[TBL] [Abstract][Full Text] [Related]
15. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
[TBL] [Abstract][Full Text] [Related]
17. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models.
Davy M; Genest L; Legrand C; Pelouin O; Froget G; Castagné V; Rupp T
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760448
[TBL] [Abstract][Full Text] [Related]
20. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]